“FDA has not approved marijuana for medical use in the United States. Despite its status as an unapproved new drug, there has been considerable interest in its use for the treatment of a number of conditions, including glaucoma, AIDS wasting, neuropathic pain, treatment of spasticity associated with multiple sclerosis, and chemotherapy-induced nausea. Under the Controlled Substances Act (CSA) Congress listed marijuana in Schedule I. Schedule I substances have a very high potential for abuse, no accepted medical use in the United States, and lack accepted safety data for use under medical supervision. Schedule I substances can still be the subject of an IND; however, the conditions for its use are more restrictive.
Pursuant to the FD&C Act, FDA is responsible for the approval and marketing of drugs for medical use, including controlled substances. DEA is the lead Federal agency responsible for regulating controlled substances and enforcing the CSA. The CSA separates controlled substances into five schedules, depending upon their approved medical use and abuse potential. Unlike Schedule I controlled substances, Schedule II substances are approved for medical use, although they also have a very high potential for abuse. Schedules III, IV, and V include those controlled substances that have been approved for medical use, but whose potential for abuse is diminished.
FDA’s Office of Criminal Investigations (OCI) is responsible for managing and conducting the Agency’s criminal investigations. As a part of its duties, OCI has worked closely with DEA on a number of criminal investigations involving the illegal sale, use, and diversion of controlled substances including controlled substances sold over the Internet. OCI’s close working relationship with DEA and local law enforcement agencies has led to many successful criminal cases involving controlled substances. FDA cooperates with DEA and other state and Federal agencies. OCI is often requested by these entities to provide assistance. Both OCI and DEA have worked together in the past to utilize the full range of regulatory and administrative tools available to them to pursue cases involving controlled substances. However, the primary responsibility for enforcing the CSA resides with DEA, and, FDA generally defers to DEA on criminal enforcement efforts related to Schedule I controlled substances. The criminal penalties related to Schedule I controlled substances are far greater under the CSA than those available under the FD&C Act for the distribution of an unapproved new drug.” -www.fda.gov
For contributions by mail, please send your name and address here
How will California defend itself against the enemy both foreign and domestic, in a newly intoxicated condition? - Not very well.
The Department of Homeland Security has the threat level in the airline sector set to level “Orange” or “High.” The next threat level would be “Red” for “Severe.” With marijuana legalization, drug paraphernalia would become yet another source of concern for airline security. We cannot afford to be casual about many items, which are banned from being brought on a plane. Drug paraphernalia would add a long list of items, which we must not be burdened with. -
DHS threat level assessment here
Animal testing must come first, to ensure Marijuana is safe and effective before human trials can begin. -www.fda.gov
History says NO, NO, NO, NO...
L.A. D.A. Steve Cooley's requests to A.G. Jerry Brown
L.A. Dispensaries shutting down
Judge Gray: Legally Tone-Deaf?
Drug Cartels will sell harder drugs: Meth, Herion, Cocaine
We're working on some more pages for this site. They will be added soon!
